Chevy Chase Trust
NKTR icon

Chevy Chase Trust’s Nektar Therapeutics NKTR Stock Holding History

Chevy Chase Trust’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-9,520
Closed -$2.6M – 1173
2019
Q3 		$2.6M Buy
9,520
+54
+0.6% +$19.8K 0.01% 536
2019
Q2 		$5.05M Buy
9,466
+19
+0.2% +$9.53K 0.02% 507
2019
Q1 		$4.54M Sell
9,447
-47
-0.5% -$27.9K 0.02% 519
2018
Q4 		$4.68M Buy
9,494
+56
+0.6% +$33.8K 0.02% 500
2018
Q3 		$8.63M Buy
9,438
+404
+4% +$345K 0.04% 447
2018
Q2 		$6.62M Sell
9,034
-32
-0.4% -$36.9K 0.03% 487
2018
Q1 		$14.4M Buy
+9,066
New +$11.7M 0.06% 310

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Chevy Chase Trust's NKTR Position: Q4 2019 in Review

Chevy Chase Trust sold out of Nektar Therapeutics (NKTR) in Q4 2019, closing a stake of 9,520 shares — an estimated $2.6M sold.

Chevy Chase Trust first reported a position in NKTR in Q1 2018 and held it in 7 quarters. The position peaked at $14.4M in Q1 2018. 281 funds tracked by Wall St. Rank hold NKTR as of Q4 2019.

  • Chevy Chase Trust reported no remaining Nektar Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Chevy Chase Trust sold 9,520 Nektar Therapeutics shares in Q4 2019, an estimated $2.6M.
  • Chevy Chase Trust first reported a position in Nektar Therapeutics in Q1 2018 and held it in 7 quarters.
  • Chevy Chase Trust's Nektar Therapeutics position peaked at $14.4M in Q1 2018.
  • 281 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2019.

Based on Chevy Chase Trust's 13F filing for Q4 2019, filed 12 Feb 2020.